SG10201909051QA - Compositions and methods for live, attenuated alphavirus formulations - Google Patents

Compositions and methods for live, attenuated alphavirus formulations

Info

Publication number
SG10201909051QA
SG10201909051QA SG10201909051QA SG10201909051QA SG 10201909051Q A SG10201909051Q A SG 10201909051QA SG 10201909051Q A SG10201909051Q A SG 10201909051QA SG 10201909051Q A SG10201909051Q A SG 10201909051QA
Authority
SG
Singapore
Prior art keywords
live
compositions
attenuated
methods
attenuated alphavirus
Prior art date
Application number
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201909051Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG10201909051QA publication Critical patent/SG10201909051QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201909051Q 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations SG10201909051QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201909051QA true SG10201909051QA (en) 2019-11-28

Family

ID=50489420

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201507462QA SG11201507462QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
SG10201801459SA SG10201801459SA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
SG10201909051Q SG10201909051QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201507462QA SG11201507462QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
SG10201801459SA SG10201801459SA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Country Status (20)

Country Link
US (2) US10137186B2 (es)
EP (2) EP3603667A1 (es)
JP (3) JP6426695B2 (es)
KR (1) KR20160003662A (es)
CN (2) CN105377293B (es)
AP (1) AP2015008733A0 (es)
AU (2) AU2014236804B2 (es)
BR (1) BR112015023205A2 (es)
CA (1) CA2903711A1 (es)
CR (1) CR20150553A (es)
DO (1) DOP2015000226A (es)
EC (1) ECSP20007842A (es)
HK (1) HK1220358A1 (es)
MX (2) MX361342B (es)
MY (1) MY178476A (es)
NZ (1) NZ631012A (es)
PH (1) PH12015502115B1 (es)
SG (3) SG11201507462QA (es)
TW (2) TWI649087B (es)
WO (1) WO2014151855A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631012A (en) 2013-03-14 2017-08-25 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
CR20180456A (es) * 2016-03-31 2019-01-09 Takeda Vaccines Inc Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
EP4282955A4 (en) * 2021-01-19 2025-01-15 Nitta Gelatin Kk VIRUS STABILIZER, GELATIN HYDROLYSATE FOR VIRUS STABILIZER, AND COMPOSITION CONTAINING VIRUS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6458560B1 (en) * 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1100944A1 (en) * 1998-07-30 2001-05-23 The Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
WO2003049763A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
CA2482448C (en) * 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2004299057B2 (en) 2003-12-17 2010-06-24 Wyeth Llc Methods for porducing storage stable viruses and immunogenic compositions thereof
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
BRPI0718548A2 (pt) 2006-11-07 2013-11-12 Sanofi Pasteur Biologics Co Estabilização de vacinas por liofilização
KR20150082667A (ko) 2007-04-06 2015-07-15 인비라젠 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
CA2698392C (en) 2007-09-04 2019-12-03 Baoming Jiang Thermal inactivation of rotavirus
KR101679812B1 (ko) 2007-09-14 2016-11-28 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
EP2250269B1 (en) 2008-01-24 2016-03-16 The Board of Regents of The University of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
EP2376107B1 (en) 2008-12-09 2014-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
JP6073031B2 (ja) 2009-12-28 2017-02-01 タケダ ヴァクシーンズ， インコーポレイテッド インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
WO2011151726A2 (en) * 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
NZ631012A (en) * 2013-03-14 2017-08-25 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations

Also Published As

Publication number Publication date
EP2968515A1 (en) 2016-01-20
HK1220358A1 (zh) 2017-05-05
US20190134182A1 (en) 2019-05-09
PH12015502115A1 (en) 2016-01-25
US10137186B2 (en) 2018-11-27
JP6426695B2 (ja) 2018-11-21
WO2014151855A1 (en) 2014-09-25
MX2015012894A (es) 2016-04-04
TW201513875A (zh) 2015-04-16
SG11201507462QA (en) 2015-10-29
MY178476A (en) 2020-10-14
CN105377293B (zh) 2020-07-17
EP2968515B1 (en) 2019-05-08
TW201900192A (zh) 2019-01-01
MX2018014977A (es) 2022-06-27
EP3603667A1 (en) 2020-02-05
DOP2015000226A (es) 2016-02-29
AU2014236804A1 (en) 2015-10-01
PH12015502115B1 (en) 2019-08-09
SG10201801459SA (en) 2018-03-28
CA2903711A1 (en) 2014-09-25
AU2018236897B2 (en) 2020-09-10
JP2020193231A (ja) 2020-12-03
MX361342B (es) 2018-12-04
US10806781B2 (en) 2020-10-20
TWI649087B (zh) 2019-02-01
JP6761015B2 (ja) 2020-09-23
ECSP20007842A (es) 2020-09-30
NZ631012A (en) 2017-08-25
CN105377293A (zh) 2016-03-02
AP2015008733A0 (en) 2015-09-30
KR20160003662A (ko) 2016-01-11
BR112015023205A2 (pt) 2017-07-18
AU2014236804B2 (en) 2018-12-13
US20140271715A1 (en) 2014-09-18
AU2018236897A1 (en) 2018-10-18
JP2019031543A (ja) 2019-02-28
CN111729077A (zh) 2020-10-02
CR20150553A (es) 2015-12-01
JP2016513658A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
CL2016001547A1 (es) Composiciones para el cuidado oral
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MX2015012737A (es) Vacunas de virus bovino liquidas estables.
GB2535876A (en) Absorbent clumping animal litter compositions
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
ZA202204981B (en) Synthetic chimeric poxviruses
PH12017500627A1 (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
BR112015028824A2 (pt) composição de tensoativo concentrada
PH12015502082A1 (en) Improved stability and potency of hemagglutinin
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2016012112A (es) Feromona tranquilizadora para gatos.
PH12018502119A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
IN2014MU00284A (es)
WO2018175580A3 (en) Development of an alternative modified live influenza b virus vaccine
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
TH179835A (th) องค์ประกอบและวิธีการสำหรับสูตรตำรับอัลฟาไวรัสซึ่งถูกทำให้อ่อนฤทธิ์ที่มีชีวิต
UA92840U (uk) Дегідратаційно-дегреасингаційний розчин для пластинації анатомічних препаратів
MY182603A (en) An extract of baeckea frutescens and its use in the treatment of gout